NEW

Top 25 Biotech Companies of 2024

Article originally published on GEN The biotechnology industry achieved many firsts this past year, from the first approved drug that can slow the rates of cognitive and functional decline in adults with Alzheimer’s disease, to the first CRISPR-based gene editing...
White Paper

Process Validation and Regulatory Review in the Age of Expedited Approval Drugs

process validation for expedited approval drugs

Expedited approval drugs have profoundly changed the thinking and approach to Process Validation and other CMC activities. When working on the development of an expedited approval drug, Chemistry, Manufacturing and Controls (CMC) data needs to be generated in about half the time of the traditional process.

Of course, an expedited approval classification does not mean that the drug developer can do less. In order to meet these accelerated timelines, analytical methods creation and product and process characterization needs to start sooner, and the process needs to be handled differently.

This paper explores those dynamics and offers some revised approach suggestions.

Download the Whitepaper

Previous

Next